Hydrocodone Combo Products Come Under FDA Microscope

In a two-day meeting that begins this morning, the FDA's Drug Safety and Risk Management (DSaRM) Advisory Committee (adcom) will examine the potential impact of rescheduling hydrocodone combination products – those mixed with other analgesics or as an antitussive – from Schedule III to II, similar to hydrocodone alone.